Cita APA (7a ed.)

Hachiya, K., Masuya, M., Kuroda, N., Yoneda, M., Tsuboi, J., Nagaharu, K., . . . Katayama, N. (2021). Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway. Nature Portfolio.

Cita Chicago Style (17a ed.)

Hachiya, Kensuke, et al. Irbesartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Colitis-associated Tumourigenesis by Blocking the MCP-1/CCR2 Pathway. Nature Portfolio, 2021.

Cita MLA (8a ed.)

Hachiya, Kensuke, et al. Irbesartan, an Angiotensin II Type 1 Receptor Blocker, Inhibits Colitis-associated Tumourigenesis by Blocking the MCP-1/CCR2 Pathway. Nature Portfolio, 2021.